ID

37428

Descripción

A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02032277

Link

https://clinicaltrials.gov/show/NCT02032277

Palabras clave

Versiones (1)
  1. 25/7/19 25/7/19 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

25 de julio de 2019

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Triple Negative Breast Cancer NCT02032277

Inglés

Eligibility Triple Negative Breast Cancer NCT02032277

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. histologically confirmed invasive breast cancer by core needle or incisional biopsy (excisional biopsy is not allowed). tumors must be clinical stage t2-3 n0-2 or t1 n1-2 per ajcc staging edition 7 or clinical stage t2-3 n0-2 or t1 n1-2 by physical exam or radiologic studies.
Descripción

Invasive carcinoma of breast Core needle biopsy | Invasive carcinoma of breast Incisional biopsy | Neoplasms TNM Breast tumor staging

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0853879
UMLS CUI [1,2]
C1318309
UMLS CUI [2,1]
C0853879
UMLS CUI [2,2]
C0184922
UMLS CUI [3,1]
C0027651
UMLS CUI [3,2]
C0474926
2. documented breast cancer gene (brca) germline mutation testing.
Descripción

BRCA gene Germ-Line Mutation Testing

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0596223
UMLS CUI [1,2]
C0206530
UMLS CUI [1,3]
C0039593
3. estrogen receptor (er)-, progesterone receptor (pr)-, and human epidermal growth factor receptor (her)2-negative (triple-negative) cancer of the breast.
Descripción

Triple Negative Breast Neoplasms

Tipo de datos

boolean

Alias
UMLS CUI [1]
C3539878
4. ecog performance status of 0 to 1.
Descripción

ECOG performance status

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1520224
5. women must be determined to be not of childbearing potential (surgically sterile, or postmenopausal defined as amenorrheic for at least 12 months) by the investigator or they must have a negative serum pregnancy test prior to randomization.
Descripción

Gender | Childbearing Potential Absent | Female Sterilization | Postmenopausal state | Childbearing Potential Serum pregnancy test negative

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0079399
UMLS CUI [2,1]
C3831118
UMLS CUI [2,2]
C0332197
UMLS CUI [3]
C0015787
UMLS CUI [4]
C0232970
UMLS CUI [5,1]
C3831118
UMLS CUI [5,2]
C0430061
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. previous anti-cancer treatment (cytotoxic chemotherapy, immunotherapy, biologic therapy radiotherapy or investigational agents) with therapeutic intent for current breast cancer.
Descripción

Cancer treatment Therapeutic intent Breast Carcinoma | Cytotoxic Chemotherapy | Immunotherapy | Biological treatment | Therapeutic radiology procedure | Investigational New Drugs

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0920425
UMLS CUI [1,2]
C0302350
UMLS CUI [1,3]
C0678222
UMLS CUI [2]
C0677881
UMLS CUI [3]
C0021083
UMLS CUI [4]
C1531518
UMLS CUI [5]
C1522449
UMLS CUI [6]
C0013230
2. previous treatment with carboplatin, paclitaxel, doxorubicin, cyclophosphamide and a poly-(adp-ribose)-polymerase (parp) inhibitor.
Descripción

Carboplatin | Paclitaxel | Doxorubicin | Cyclophosphamide | Poly(ADP-ribose) Polymerase Inhibitors

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0079083
UMLS CUI [2]
C0144576
UMLS CUI [3]
C0013089
UMLS CUI [4]
C0010583
UMLS CUI [5]
C1882413
3. concurrent treatment with an ovarian hormonal replacement therapy or with hormonal agents such as raloxifene, tamoxifen or other selective estrogen receptor modulator (serm). subjects must have discontinued use of such agents prior to beginning study treatment.
Descripción

Hormone replacement therapy ovarian | Pharmaceutical Preparations Hormonal To be stopped | Raloxifene | Tamoxifen | Selective Estrogen Receptor Modulators

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0282402
UMLS CUI [1,2]
C0205065
UMLS CUI [2,1]
C0013227
UMLS CUI [2,2]
C0458083
UMLS CUI [2,3]
C1272691
UMLS CUI [3]
C0244404
UMLS CUI [4]
C0039286
UMLS CUI [5]
C0732611
4. a history of seizure within 12 months prior to study entry.
Descripción

Seizure

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0036572
5. pre-existing neuropathy from any cause in excess of grade 1.
Descripción

Neuropathy Pre-existing CTCAE Grades

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0442874
UMLS CUI [1,2]
C2347662
UMLS CUI [1,3]
C1516728
Volver a la parte superior de la página

Similar models

Eligibility Triple Negative Breast Cancer NCT02032277

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Invasive carcinoma of breast Core needle biopsy | Invasive carcinoma of breast Incisional biopsy | Neoplasms TNM Breast tumor staging
Item
1. histologically confirmed invasive breast cancer by core needle or incisional biopsy (excisional biopsy is not allowed). tumors must be clinical stage t2-3 n0-2 or t1 n1-2 per ajcc staging edition 7 or clinical stage t2-3 n0-2 or t1 n1-2 by physical exam or radiologic studies.
boolean
C0853879 (UMLS CUI [1,1])
C1318309 (UMLS CUI [1,2])
C0853879 (UMLS CUI [2,1])
C0184922 (UMLS CUI [2,2])
C0027651 (UMLS CUI [3,1])
C0474926 (UMLS CUI [3,2])
BRCA gene Germ-Line Mutation Testing
Item
2. documented breast cancer gene (brca) germline mutation testing.
boolean
C0596223 (UMLS CUI [1,1])
C0206530 (UMLS CUI [1,2])
C0039593 (UMLS CUI [1,3])
Triple Negative Breast Neoplasms
Item
3. estrogen receptor (er)-, progesterone receptor (pr)-, and human epidermal growth factor receptor (her)2-negative (triple-negative) cancer of the breast.
boolean
C3539878 (UMLS CUI [1])
ECOG performance status
Item
4. ecog performance status of 0 to 1.
boolean
C1520224 (UMLS CUI [1])
Gender | Childbearing Potential Absent | Female Sterilization | Postmenopausal state | Childbearing Potential Serum pregnancy test negative
Item
5. women must be determined to be not of childbearing potential (surgically sterile, or postmenopausal defined as amenorrheic for at least 12 months) by the investigator or they must have a negative serum pregnancy test prior to randomization.
boolean
C0079399 (UMLS CUI [1])
C3831118 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0015787 (UMLS CUI [3])
C0232970 (UMLS CUI [4])
C3831118 (UMLS CUI [5,1])
C0430061 (UMLS CUI [5,2])
Item Group
C0680251 (UMLS CUI)
Cancer treatment Therapeutic intent Breast Carcinoma | Cytotoxic Chemotherapy | Immunotherapy | Biological treatment | Therapeutic radiology procedure | Investigational New Drugs
Item
1. previous anti-cancer treatment (cytotoxic chemotherapy, immunotherapy, biologic therapy radiotherapy or investigational agents) with therapeutic intent for current breast cancer.
boolean
C0920425 (UMLS CUI [1,1])
C0302350 (UMLS CUI [1,2])
C0678222 (UMLS CUI [1,3])
C0677881 (UMLS CUI [2])
C0021083 (UMLS CUI [3])
C1531518 (UMLS CUI [4])
C1522449 (UMLS CUI [5])
C0013230 (UMLS CUI [6])
Carboplatin | Paclitaxel | Doxorubicin | Cyclophosphamide | Poly(ADP-ribose) Polymerase Inhibitors
Item
2. previous treatment with carboplatin, paclitaxel, doxorubicin, cyclophosphamide and a poly-(adp-ribose)-polymerase (parp) inhibitor.
boolean
C0079083 (UMLS CUI [1])
C0144576 (UMLS CUI [2])
C0013089 (UMLS CUI [3])
C0010583 (UMLS CUI [4])
C1882413 (UMLS CUI [5])
Hormone replacement therapy ovarian | Pharmaceutical Preparations Hormonal To be stopped | Raloxifene | Tamoxifen | Selective Estrogen Receptor Modulators
Item
3. concurrent treatment with an ovarian hormonal replacement therapy or with hormonal agents such as raloxifene, tamoxifen or other selective estrogen receptor modulator (serm). subjects must have discontinued use of such agents prior to beginning study treatment.
boolean
C0282402 (UMLS CUI [1,1])
C0205065 (UMLS CUI [1,2])
C0013227 (UMLS CUI [2,1])
C0458083 (UMLS CUI [2,2])
C1272691 (UMLS CUI [2,3])
C0244404 (UMLS CUI [3])
C0039286 (UMLS CUI [4])
C0732611 (UMLS CUI [5])
Seizure
Item
4. a history of seizure within 12 months prior to study entry.
boolean
C0036572 (UMLS CUI [1])
Neuropathy Pre-existing CTCAE Grades
Item
5. pre-existing neuropathy from any cause in excess of grade 1.
boolean
C0442874 (UMLS CUI [1,1])
C2347662 (UMLS CUI [1,2])
C1516728 (UMLS CUI [1,3])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial